


## PHARMACEUTICAL 2021

## RespireRx Pharmaceuticals Inc. Rank 362 of 409





## PHARMACEUTICAL 2021

## RespireRx Pharmaceuticals Inc. Rank 362 of 409

The relative strengths and weaknesses of RespireRx Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RespireRx Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 1,911% points. The greatest weakness of RespireRx Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 317% points.

The company's Economic Capital Ratio, given in the ranking table, is -640%, being 285% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	85
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,148
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	546
Other Liabilities	0
Other Net Income	-440
Property and Equipment	0
Research and Development	638
Revenues	0
Selling, General and Administrative Expense	2,677

Output Variable	Value in 1000 USD
Assets	85
Liabilities	8,148
Expenses	3,861
Stockholders Equity	-8,063
Net Income	-4,301
Comprehensive Net Income	-4,301
Economic Capital Ratio	-640%